Negaban (temocillin) / Eumedica - LARVOL DELTA

Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producing Klebsiella pneumoniae isolates in a hollow-fiber infection model. (PubMed, Antimicrob Agents Chemother) - "While both regimens demonstrated initial bactericidal activity, CI was more effective in sustaining bacterial suppression and limiting resistance emergence. These findings support the potential clinical benefit of CI for treating infections caused by CTX-M-15-producing K. pneumoniae and warrant further clinical validation."

Journal • PK/PD data • Infectious Disease • Pneumonia

Method validation for the detection of multidrug-resistant Enterobacterales in hospital aquatic environment. (PubMed, J Hosp Infect) - "These results suggest that for the detection of multidrug-resistant pathogens in the hospital aquatic environment, swabbing of sink P-traps and water collection from toilets combined with enrichment are the most suitable methods."

Journal

Adaptation and performance evaluation of the French society of microbiology algorithm for detection of carbapenemase-producing enterobacterales using VITEK2 antibiotic susceptibility testing system. (PubMed, Eur J Clin Microbiol Infect Dis) - "The adapted CA-SFM algorithm offers enhanced detection of CPE, particularly for OXA-48-like strains with weak carbapenem hydrolysis, which are often missed by carbapenem MIC-based methods alone. Given the clinical risks of under-detection and transmission, implementing the adapted CA-SFM algorithm strategy could strengthen infection control and antimicrobial stewardship efforts."

Journal • Infectious Disease

Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study. (PubMed, J Antimicrob Chemother) - "In this study, compared with other beta-lactams, temocillin was not associated with an increased risk of early clinical failure in the treatment of 3GC-R Enterobacterales UTIs."

Journal • Retrospective data • Infectious Disease • Nephrology

Temocillin: A Narrative Review of Its Clinical Reappraisal. (PubMed, Antibiotics (Basel)) - "It also exhibits synergistic activity with agents like fosfomycin, further enhancing its clinical value. Most of the current evidence is derived from retrospective and observational studies. Temocillin emerges as a promising carbapenem-sparing option for the treatment of challenging infections caused by multidrug-resistant Gram-negative bacteria."

Journal • Review • Infectious Disease • Nephrology • Pediatrics • Pneumonia • Respiratory Diseases

TEMOKID-POP: Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris

New trial • Nephrology

Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae. (PubMed, J Antimicrob Chemother) - No abstract available

Journal • Infectious Disease

Role of S155, D159 and R214 Amino-Acid Residues in the Active Site of OXA-48 Variants (ASM Microbe 2025) - "All S155 A, K, D and T substitutions display a drastic reduction in carbapenem and temocillin hydrolytic activity of OXA-48, except for S155M...Our work further illustrates the remarkable propensity of OXA-48-like carbapenemases to evolve through mutations at positions outside the β5-β6 loop, but interacting with key residues of it. Our result further support the role of the salt bridge between R214 and D159, its stabilization by S155, to maintain the conformation and network of water molecules in the active site."

SCREENING CONUNDRUM AFTER UNEXPECTED POSTOPERATIVE IDENTIFICATION OF BLAOXA-48-LIKE CARBAPENEMASE-PRODUCING E.COLI (ESPID 2025) - "Culture of CSF leakage from the wound, observed on day 6 post-op, yielded blaOXA-244 E.coli sensitive to meropenem and ertapenem but resistant to temocillin and piperacillin-tazobactam (PTZ)...The child was treated with a combination of intrathecal gentamicin, IV meropenem and ceftazidime-avibactam...Learning Points/Discussion BlaOXA-48-like organisms are notoriously difficult to detect on routine meropenem containing CPE screening agars. This incidence highlights diagnostic limitations in detecting OXA-48-like CPE organisms, the necessity of tailored protocols in high-risk settings and vigilant postoperative surveillance."

Infectious Disease

Assessment of Phenotypic Tools for Detection of OXA-48, KPC, and NDM in Klebsiella pneumoniae in Oman. (PubMed, Diagnostics (Basel)) - " In total, 80 GeneXpert/PCR-confirmed (40 OXA-48 and 20 KPC and NDM each) and 37 whole-genome-sequenced (25 OXA-232 and 6 KPC-2, plus NDM-1 and NDM-5) K. pneumoniae were subjected to screening by temocillin (30 μg disk) (MAST Diagnostica, Germany) and D71C (MASTDISCS®)...With high sensitivity and specificity, ease of performance, short turnaround time, and low cost, we recommend the ICT format for routine diagnostic use. In resource-constrained centers, the OXA-48 disk test is an excellent alternative with high sensitivity and specificity."

Journal • Infectious Disease • Pneumonia

Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms. (PubMed, Arch Microbiol) - "Porin modifications reduce the influx of antibiotics, whereas overexpression of efflux pumps, particularly those in the resistance-nodulation-cell division (RND) family, actively expels antibiotics from bacterial cells, significantly lowering intracellular drug concentrations and leading to treatment failure.This review examines the mechanisms of action, resistance profiles, and pharmacokinetic/pharmacodynamic characteristics of newly developed antibiotics designed to combat infections caused by MDR and carbapenem-resistant Gram-negative pathogens. The antibiotics discussed include ceftazidime-avibactam, imipenem-relebactam, ceftolozane-tazobactam, meropenem-vaborbactam, aztreonam-avibactam, delafloxacin, temocillin, plazomicin, cefiderocol, and eravacycline."

Journal • Review • Critical care • Infectious Disease

Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial (ESCMID Global 2025) - No abstract available

Clinical • Late-breaking abstract

Pharmacodynamic optimisation of temocillin treatment against CTX-M-15-producing K. pneumoniae isolates in a hollow-fiber infection model (ESCMID Global 2025) - No abstract available

PK/PD data • Infectious Disease • Pneumonia

Population pharmacokinetic/pharmacodynamic analysis of intravenous temocillin for the treatment of 3rd generation cephalosporin-resistant Escherichia coli bacteraemia (ASTARTE study) (ESCMID Global 2025) - No abstract available

Clinical • PK/PD data

Treatment failure rates do not differ according to temocillin MIC in the treatment of Enterobacterales blood stream infection: an observational study (ESCMID Global 2025) - No abstract available

Clinical • Observational data • Infectious Disease

Rapid detection of temocillin resistance in third-generation cephalosporin resistant Enterobacteriaceae (ESCMID Global 2025) - No abstract available

Temocillin efficacy and emergence of resistance in Enterobacter cloacae complex in a murine peritonitis model (ESCMID Global 2025) - No abstract available

Preclinical

Evaluation of meropenem, ertapenem and temocillin screening breakpoints in the EUCAST rapid antimicrobial susceptibility testing (RAST) for rapid detection of OXA-48-producing Klebsiella pneumoniae directly from positive blood cultures (ESCMID Global 2025) - No abstract available

Infectious Disease • Pneumonia

Performance of antibiotic susceptibility testing methods for novel beta-lactam/beta-lactamase inhibitors and temocillin in carbapenemase-producing Enterobacterales: a comparative study (ESCMID Global 2025) - No abstract available

Prevalence and risk factors of antibiotic resistance for urinary tract infections in patients presenting to a Belgian tertiary care emergency department: testing the national guidelines against the local setting. (PubMed, Acta Clin Belg) - "Overall, fosfomycin (29.2%) and nitrofurantoin (28.6%) showed the highest resistance rates. Ceftriaxone revealed lower resistance rates (13.1%) compared to ciprofloxacin (17.0%) and cefuroxime (18.4%)...However, overall, and especially in patients at risk for ESBL-producing bacteria, temocillin would be an even better choice in our setting. National microbiological data should be reviewed to support recommending temocillin as a first-line antibiotic in patients presenting with upper UTI."

Journal • Infectious Disease • Nephrology

Interspecies differences in Plasma Protein Binding of Beta-Lactam Antibiotics. (PubMed, Int J Antimicrob Agents) - "Significant variability in protein binding was observed among and between different species for the tested drugs. The study highlights substantial interspecies differences in the plasma protein binding of cefiderocol, ceftriaxone, and temocillin. Our findings indicate the need for careful consideration of species-specific PPB in the optimization of beta-lactam dosing and the development of new pharmaceuticals."

Journal

Preserving the antimicrobial arsenal: exploring alternatives to carbapenems in ESBL battles within the southeast of Ireland. (PubMed, J Med Microbiol) - "Temocillin (TMC), mecillinam (MEC), cefiderocol (FDC), amikacin and fosfomycin (FOS) displayed excellent activity against all ESBL-PE isolates tested, with susceptibility rates of≥85%. Ciprofloxacin and amoxicillin-clavulanic acid were the least efficacious agents, with susceptibility rates≤20%.Conclusions. TMC, MEC, FDC and FOS offer promising alternatives to carbapenems, demonstrating efficacy against ESBL-PE. The use of these agents not only broadens the therapeutic arsenal against ESBL-PE but also mitigates the potential for escalating carbapenem resistance, especially in regions where the incidence of carbapenem resistance is increasing."

Journal • Infectious Disease

Variable temocillin protein binding and pharmacokinetics in different clinical conditions: Implications for target attainment. (PubMed, Br J Clin Pharmacol) - "Our study underscores the significant variation in temocillin clearance and unbound fractions among different participant groups, challenging the efficacy of traditional 2 g q12h dosing. For patients with enhanced renal function and lower inflammation, continuous infusion emerges as a more effective strategy to achieve optimal target attainment."

Journal • PK/PD data • Infectious Disease • Inflammation • Nephrology • Septic Shock • CRP

Population pharmacokinetics and dosing simulations of temocillin in liver transplanted paediatric patients: a prospective, open-label, non-randomized study. (PubMed, Clin Microbiol Infect) - "Although adequate in many instances, the current dosing regimen is likely inadequate for patients with low body weight, high renal function, or bacteria with high MIC, emphasizing the need for patient-specific factors to be considered in dose selection. These data support the importance of paediatric pharmacokinetic studies to optimize drug dosing regimens."

Journal • PK/PD data • Hepatology • Infectious Disease • Pediatrics • Transplantation

Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime? (PubMed, J Antimicrob Chemother) - "Temocillin appears to be reliable for ABPE infections. Our data showed a high therapeutic success rate. Its high tolerability, narrow spectrum and ease of administration could make temocillin a relevant alternative to cefepime, the current standard for ABPE infection."

Journal • Infectious Disease • Nephrology